Oncology Research

Papers
(The TQCC of Oncology Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Galectins dysregulation: A way for cancer cells to invade and pervade47
Has_circ_0000069 expression in breast cancer and its influences on prognosis and cellular activities35
Inhibition of apoptosis-regulatory protein Siva-1 reverses multidrug resistance in gastric cancer by targeting PCBP134
Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer29
Survival and comorbidities in lung cancer patients: Evidence from administrative claims data in Germany28
Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations27
Long noncoding RNA TFAP2A AS1 exerts promotive effects in non small cell lung cancer progression via controlling the microRNA 548a 3p/CDK4 axis26
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma26
System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer25
A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells24
The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway21
Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis19
Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas18
Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data18
Identification of lncRNAs associated with the progression of acute lymphoblastic leukemia using a competing endogenous RNAs network17
Is autophagy induction by PARP inhibitors a target for therapeutic benefit?16
The role of LIN28B in tumor progression and metastasis in solid tumor entities14
Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer14
Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma13
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance13
Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study13
Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells12
YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells12
The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells11
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials11
Deoxynortryptoquivaline: A unique antiprostate cancer agent11
0.041690111160278